Detailed Narrative
Custom Synthesis Momentum: Multiple Long-Term Agreements
Custom synthesis contributed 54% of FY25 revenue, up from historical levels. Two major long-term supply agreements signed (~₹700 crores each) - one for an active API and another for advanced intermediates. Commercialization expected late 2026/early 2027 post regulatory approvals. Strong RFP pipeline driven by both organic demand and China Plus One/Biosecure Act tailwinds. Company working with innovators on GLP-1, GIP, GLP-2 analogs and small molecules across various development phases.
Kakinada Unit-III: Backward Integration Scaling
Phase 1 production commenced January 2025 on 200 of 500 total acres with 7 production blocks. Total spend of ₹1,497 crores with ~₹200 crores remaining for Phase 1 completion. Backward integration benefits beginning to flow into product costs. Phase 1 also frees capacity at Unit I and Unit II for GMP products while Kakinada goes through its own regulatory phase. Phase 2 expansion plans depend on market opportunities with 300 acres available.
Margin Expansion: Operating Leverage and Product Mix
FY25 EBITDA margins expanded from 29% to 32% driven by favorable product mix (higher CS share), operating leverage on 18% constant currency growth, and other expenses declining from 17% to 14% of sales. Material consumption stable at ~40% of sales. Forex gains of ₹48 crores for FY25. Management expects quarter-to-quarter margin variability based on product mix but targets consistent double-digit growth trajectory.
Peptide and Emerging Capabilities Investment
Active investments in both solid-phase and liquid-phase peptide synthesis for GLP-1 and related molecules. Working exclusively with innovators rather than generic peptide market. Continuous flow chemistry and biocatalysis being deployed for sustainable manufacturing. ADCs and nucleotides in preliminary phases. Cash position of ₹3,696 crores provides ample firepower for capacity expansion as CS opportunities materialize.